The present invention as described herein is aimed at combining a radiation-induced immunogenic effect with a T-cell therapy technique to markedly improve the therapeutic effectiveness of adoptive T-cell therapy with minimized toxicity. The method of this invention comprises, identifying a target tumor, applying ablative radiation treatment to the tumor in-situ, waiting for the production of CTLs primed by antigen presenting cells (APC), then resecting the target tumor from the patient. The CTLs are harvested and isolated from the tumor and undergo ex-vivo expansion and subsequent treatment of immune checkpoint blockades. The expanded CTLs are then infused back into the patient for systemic treatment of microscopic disease. The primed CTLs that are induced by radiation in-situ, are used as the source of T-cell therapy or other types of cell therapy. The harvested CTLs will have high tumor specificity with a wide range of heterogeneous tumor associated antigens (TAA) presentation.
